A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Modakafusp alfa (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms iinnovate-2
- Sponsors Takeda; Takeda Development Center Americas
Most Recent Events
- 19 Jul 2024 Status changed from active, no longer recruiting to completed.
- 31 May 2024 Planned End Date changed from 25 Jan 2028 to 4 Jun 2024.
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.